FIELD: biochemistry.
SUBSTANCE: invention relates to a bispecific binding molecule which specifically binds to human ROR1 and human CD3, as well as to an immunoconjugate, a pharmaceutical composition, a kit and a bottle containing it. Also disclosed is an isolated nucleic acid molecule coding said antibody, as well as a vector and a cell containing same. Invention also relates to a method of producing a bispecific binding molecule involving the use of said cells.
EFFECT: invention is effective for treating ROR1-positive cancer in a patient.
50 cl, 29 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| ANTI-CD137 ANTIGEN-BINDING MOLECULES AND USE THEREOF | 2019 |
|
RU2829536C2 |
| ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| ANTI-CEACAM6 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2739163C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
